Research Analysts’ Recent Ratings Changes for Phreesia (PHR)

A number of research firms have changed their ratings and price targets for Phreesia (NYSE: PHR):

• 9/8/2026 – Phreesia was downgraded by Raymond James Financial, Inc. from “outperform” to “market perform”.
• 9/5/2026 – Phreesia was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/4/2026 – Phreesia was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/4/2026 – Phreesia had its price target lowered by DA Davidson from $14.00 to $13.00. They now have a “buy” rating on the stock.
• 9/4/2026 – Phreesia had its price target raised by Robert W. Baird from $10.00 to $11.00. They now have a “neutral” rating on the stock.
• 9/4/2026 – Phreesia had its “market perform” rating reaffirmed by Citigroup Inc..
• 9/3/2026 – Phreesia had its price target raised by Wells Fargo & Company from $9.00 to $10.00. They now have an “equal weight” rating on the stock.
• 9/3/2026 – Phreesia had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $19.00 price target on the stock.
• 9/3/2026 – Phreesia had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $16.00 price target on the stock.
• 8/31/2026 – Phreesia had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $14.00 price target on the stock.

Insider Buying and Selling

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,662 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $10.08, for a total value of $67,152.96. Following the transaction, the general counsel directly owned 266,574 shares of the company’s stock, valued at $2,687,065.92. This trade represents a 2.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 10,579 shares of company stock valued at $106,278. 5.20% of the stock is currently owned by corporate insiders.

Phreesia, Inc is a healthcare technology company that provides software and services designed to help healthcare organizations manage patient intake and engagement. Its platform digitizes administrative and clinical processes that traditionally rely on paper forms, manual data entry, and separate payment systems.

The company’s offerings include digital patient check-in and registration, insurance and demographic information collection, appointment-related communications, electronic forms and consent management, patient surveys, and payment processing.